HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome.

AbstractAIMS:
Preeclampsia (PE) is considered a uniformly progressive disease, however, it shows a different pattern of clinical progression in patients with early (<34 weeks) or late (≥ 34 weeks) onset of the disease. Angiogenic factors such as soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF) are closely related to the clinical course of PE. We evaluated sFlt-1 and PlGF levels in the clinical course of PE in women admitted with a diagnosis of PE at different gestational ages.
METHODS:
This retrospective study included 34 patients with PE, of which 11 patients had HELLP syndrome (over a period of 3 years). Serial measurements of sFlt-1 and PlGF were completed from admission until delivery. Values are presented as mean ± standard deviation.
RESULTS:
Mean gestational age of admission among women with early onset PE was significantly lower, at 29 ± 3 weeks compared to 37±1 weeks among patients with late onset disease. Mean prolongation of pregnancy was 6 days, which was similar within the two groups. Compared to women with late onset PE, women with early-onset PE had a greater increase in sFlt-1 (11% vs. 3% per day, P<0.05), greater decrease in PlGF levels (21% vs. 10% per day, P=0.30), resulting in a much higher increase in sFlt-1/PlGF ratio (23% vs. 8% per day, P<0.05). Patients with HELLP syndrome showed comparable progression patterns.
CONCLUSION:
In a similar way to the progressively worsening clinical course observed in women with early onset PE, there were changes in the angiogenic profile that leads to a more anti-angiogenic state in these women with each passing day. These findings may have implications in identification of the women for appropriate patient management and possible future therapies based on the reduction of sFlt-1 levels.
AuthorsWiebke Schaarschmidt, Sarosh Rana, Holger Stepan
JournalJournal of perinatal medicine (J Perinat Med) Vol. 41 Issue 5 Pg. 511-6 (Sep 01 2013) ISSN: 1619-3997 [Electronic] Germany
PMID23612628 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Angiogenesis Inhibitors
  • Biomarkers
  • PGF protein, human
  • Pregnancy Proteins
  • Placenta Growth Factor
  • FLT1 protein, human
  • Vascular Endothelial Growth Factor Receptor-1
Topics
  • Adult
  • Angiogenesis Inhibitors (blood)
  • Biomarkers (blood)
  • Cohort Studies
  • Female
  • HELLP Syndrome (blood, diagnosis)
  • Humans
  • Placenta Growth Factor
  • Pre-Eclampsia (blood, diagnosis)
  • Pregnancy
  • Pregnancy Proteins (blood)
  • Pregnancy Trimester, Third
  • Retrospective Studies
  • Vascular Endothelial Growth Factor Receptor-1 (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: